The American pharmaceutical Pfizer expects to request an emergency authorization for the use of a vaccine against covid-19 in the third week of November, the president of the company announced this Friday.
“Assuming the data is positive, Pfizer will apply for an emergency use authorization in the United States shortly after the security step is reached in the third week of November,” said Albert Bourla in an open letter published Friday in his page on the Internet.
The United States may have two vaccines ready by the end of the year, if ongoing clinical trials are successful and if the drug agency (FDA) authorizes their distribution, since Moderna also points to November, after the US presidential elections.
U.S. President Donald Trump, who is running for a second term, said a vaccine could be available before the November 3 elections.
Pfizer followed instructions from the FDA, which last week asked vaccine promoters to wait two months after the second dose was injected into clinical trial participants to monitor for the appearance of any serious side effects.
The pharmaceutical company’s shares were up more than 2% in e-commerce before the opening of the exchange.
The president of Pfizer, a partner of the German company BioNTech, said that the ongoing trial involving 30,000 people could produce results on the vaccine’s effectiveness in the next two weeks.
“We will be able to know whether or not our vaccine is effective by the end of October,” wrote Albert Bourla.
The FDA establishes three conditions for approving a vaccine: whether it is effective, whether it is safe, and whether the company is capable of producing it on a large scale. Pfizer believes that the three conditions will be met by the third week of November, within a month.
The date is similar to that advanced last week by another company, Moderna, more advanced in clinical trials, whose responsible mentioned the 25th of November.